GT719 not checked

Grit Biotechnology

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Hematological Malignancy (Leukemia- Lymphoma), Neurological Autoimmune Diseases
Main trialPhase 1/2
“This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.”In the company’s words, NCT06948981 on ClinicalTrials.gov

Other drugs for Hematological Malignancy (Leukemia- Lymphoma)

All 105 drugs for Hematological Malignancy (Leukemia- Lymphoma)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 17 Apr 2028 GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Phase 1Recruiting 13 Jan 2028 GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow GT719

Following is part of Solo: you see every change to GT719 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in